Soligenix (SNGX) investor relations material

Executive summary

• Net loss for 2025 was $11.1 million, a 34% increase from 2024, driven by higher R&D expenses and lower other income.

• No revenues were recognized in 2025, compared to $119,371 in 2024, due to the conclusion of a grant-funded study.

• The company operates two segments: Specialized BioTherapeutics (focused on HyBryte™ for CTCL and other indications) and Public Health Solutions (vaccines and therapeutics for biodefense and infectious diseases).

Financial highlights

• Research and development expenses rose 43% to $7.5 million in 2025, mainly due to Phase 2a BD and Phase 3 CTCL studies.

• General and administrative expenses increased 3% to $4.4 million, primarily from higher franchise taxes and stock-related costs.

• Cash and cash equivalents were $7.9 million at year-end 2025, with working capital of $5.1 million.

• The company sold New Jersey NOL carryforwards, recognizing $506,615 in income tax benefit.

Outlook and guidance

• Cash on hand is expected to support operations into Q4 2026, but not for a full 12 months post-filing, raising substantial doubt about going concern.

• Plans to secure additional capital through equity offerings, government grants, and strategic transactions.

• No contract or grant reimbursements are anticipated in 2026; R&D expenditures are projected at $3.3 million.